1. "2018"
Formats
  1. Journal Article (3011)
  2. Meeting Abstract (1948)
  3. Book Section (206)
  4. Conference Paper (38)
  5. Book Whole (11)
  6. Editorial (4)
  7. Review (4)
  8. Miscellaneous (2)
  9. Correspondence (1)
Groups
  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)

More Groups

People
  1. Sergio Giralt (87)
  2. Matthew Hellmann (78)
  3. Jedd Wolchok (74)
  4. Marc Ladanyi (74)
  5. Robert Motzer (71)
  6. Nancy Lee (64)

More People

Years
  1. 2018 (5225)
Publications
  1. Journal of Clinical Oncology (562)
  2. Blood (249)
  3. Cancer Research (183)
  4. Annals of Oncology (140)
  5. International Journal of Radiation Oncology, Biology, Physics (137)
  6. Modern Pathology (127)

More Publications

Publishers
  1. Elsevier Inc. (691)
  2. American Society of Clinical Oncology (605)
  3. Springer (410)
  4. American Association for Cancer Research (299)
  5. Oxford University Press (291)
  6. American Society of Hematology (273)

More Publishers

Results (5225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance)
    Meeting Abstract

    Tanioka, M.; Parker, J. S.; Henry, L. N.; Tolaney, S.; Dang, C.; Krop, I. E.; Harris, L.; Hillman, D.; Polley, M.; Berry, D. A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
    Meeting Abstract

    Pernas, S.; Villagrasa, P.; Vivancos, A.; Scaltriti, M.; Rodon, J.; Burgues, O.; Nuciforo, P. G.; Canes, J.; Dueñas, M.; Vidal, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)
    Meeting Abstract

    Hargrave, D.; Witt, O.; Cohen, K.; Packer, R.; Lissat, A.; Kordes, U.; Laetsch, T. W.; Hoffman, L.; Lassaletta, A.; Gerber, N. U.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Meeting Abstract

    Yoshino, T.; Iwata, H.; Tamura, K.; Takahashi, S.; Redfern, C.; Modi, S.; Doi, T.; Kawakami, H.; Taniguchi, H.; Takashima, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Yau, T.; Cheng, A. L.; Meyer, T.; Ryoo, B. Y.; Park, J. W.; Klümpen, H. J.; Lim, H. Y.; Kim, S.; Knox, J.; Patel, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Characterization of PD-L1, CD8, CD3, CD68 and PanCK in tumor microenvironment of Gl tract tumors with respect to patients' mismatch repair status and anti-PD-1 treatment outcome using 5Plex IHC and whole slide image analysis
    Meeting Abstract

    Zhang, W.; Khojasteh, M.; Hubbard, A.; Martin, J.; Wang, X.; Kamthamraju, S.; Munoz-Rodriguez, J. L.; Jiang, D.; Cai, Z.; Li, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
    Meeting Abstract

    Yao, J. C.; Strosberg, J.; Fazio, N.; Pavel, M. E.; Ruszniewski, P.; Bergsland, E.; Li, D.; Tafuto, S.; Raj, N.; Campana, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of tabelecleucel in patients with EpsteinBarr Virus-associated leiomyosarcomas (EBV(+)LMS)
    Meeting Abstract

    Kurlander, L. S.; Srinivasan, A.; Ghobadi, A.; Suser, S.; Doubrovina, E.; Boulad, F.; Mascarenhas, L.; Laquaglia, M.; Price, A.; Behr, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Tolaney, S. M.; Seidman, A. D.; Anders, C. K.; Ibrahim, N. K.; Rugo, H. S.; Twelves, C. J.; Dieras, V.; Müller, V.; Hannah, A. L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save